You are here:

Cambium Enrolls First Patient in Phase I/II Study to Evaluate Platelet Lysate Biologic for Graft-vs.-Host Disease Dry Eye

ATLANTA, GA – June 15, 2018 – Cambium Medical Technologies (“Cambium”), a clinical stage company, announced today first patient enrollment for its Elate Ocular™ topical fibrinogen-depleted human platelet lysate biologic in a randomized, multicenter, double-masked placebo-controlled parallel Phase I/II study. The study is designed to determine safety and exploratory efficacy in patients with dry eye ...
Read more

FDA Notifies Cambium Phase I/II Dry Eye Study Can Proceed

Study for Graft vs. Host Disease Dry Eye to Begin Late 2017/Early 2018 ATLANTA, GA – September 29, 2017 – Cambium Medical Technologies (“Cambium”), a clinical stage company, announced today that the U.S. Food & Drug Administration (“FDA”) notified Cambium on September 22 it has completed review of Cambium’s Investigational New Drug Application (IND) submitted ...
Read more

Cambium Medical Technologies Announces Major Development And Collaboration Agreement with Pacific Rim Partner

Gwowei Technology Company, Ltd., Taiwan, to Join Cambium in Development and Commercialization of Certain Human Platelet Derived Research and Therapeutic Products ATLANTA, GA – May 19, 2014 – Cambium Medical Technologies (“Cambium” or “the Company’) announced today the signing of a Joint Development and Collaboration Agreement (“JDCA”) with a U.S. subsidiary of Gwowei Technology Company ...
Read more